戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 epidemiologic risk factor for acquisition of Blastomyces.
2                      We investigated whether blastomyces adhesin 1 (BAD1) exploits host receptors for
3                                       BAD-1 (Blastomyces adhesin 1), a 120-kDa protein of Blastomyces
4 nary isolates of B. helicus identified among Blastomyces and Emmonsia isolates at the University of A
5 f the high level of cross-reactivity between Blastomyces and Histoplasma antigen EIAs, utilization of
6 t with both of the commonly used, individual Blastomyces and Histoplasma antigen EIAs.
7 say (EIA) (Portland, Maine) for detection of Blastomyces and Histoplasma antigens in serum.
8 were not resolved and the nearest outgroups (Blastomyces and Paracoccidioides) were too distant to un
9 e assessed performance of the Gotham BioTech Blastomyces antigen (GBA) enzyme immunoassay (EIA) (Port
10                              Histoplasma and Blastomyces antigen detection assays are commonly used d
11 lysis of 3,529 patients with Histoplasma and Blastomyces antigen testing performed on the same serum
12  within thermally dimorphic fungi (genera of Blastomyces, Coccidioides and Histoplasma).
13 or five major fungal pathogens: Aspergillus, Blastomyces, Coccidioides, Cryptococcus, and Histoplasma
14 United States-Histoplasma, Coccidioides, and Blastomyces-commonly known as endemic mycoses of North A
15 ew assay permitted retrospective analysis of Blastomyces cultures and primary clinical specimens from
16                   We recently discovered the Blastomyces Dectin-2 ligand endoglucanase 2 that harbors
17 ed by O-mannans decorating the C terminus of Blastomyces Dectin-2 ligand endoglucanase 2, can augment
18 fungal pulmonary infections with two agents, Blastomyces dermatitidis an extracellular pathogen, and
19 D4(+) T cells respond to a native epitope in Blastomyces dermatitidis and also in Histoplasma capsula
20 disease known in North America and caused by Blastomyces dermatitidis and B. gilchristii.
21                         Blastomycosis due to Blastomyces dermatitidis and Blastomyces gilchristii is
22 disease known in North America and caused by Blastomyces dermatitidis and Blastomyces gilchristii.
23 at regulates dimorphism and pathogenicity in Blastomyces dermatitidis and H. capsulatum.
24                                              Blastomyces dermatitidis and Histoplasma capsulatum are
25              Herein, we investigated whether Blastomyces dermatitidis and Histoplasma capsulatum-infe
26 dhesin is indispensable for pathogenicity of Blastomyces dermatitidis and is thought to promote pulmo
27 g of the molecular bases of pathogenicity in Blastomyces dermatitidis and related systemic dimorphic
28      We report results of an immunoassay for Blastomyces dermatitidis antigenuria.
29 n real-time PCR assay was developed from the Blastomyces dermatitidis BAD1 gene promoter.
30 inically important discrepancy was observed (Blastomyces dermatitidis by culture and Cryptococcus neo
31 40/CD40L interactions in vaccine immunity to Blastomyces dermatitidis by immunizing CD40(-/-) and CD4
32                The dimorphic fungal pathogen Blastomyces dermatitidis can infect immunocompetent pati
33 cally engineered, live, attenuated strain of Blastomyces dermatitidis carrying a targeted deletion at
34 e (3-week-old) mice killed nonphagocytizable Blastomyces dermatitidis cells less (25%) than did cells
35        Recent studies showed that attenuated Blastomyces dermatitidis confers protection via T cell r
36 ast cytosol extract (YCE) crude antigen from Blastomyces dermatitidis confers T-cell-mediated resista
37  in South Africa between 1967 and 2014, with Blastomyces dermatitidis considered to be the etiologica
38 ld was found to be positive by the AccuProbe Blastomyces dermatitidis Culture ID Test (Gen-Probe Inc.
39                         People infected with Blastomyces dermatitidis develop strong immunity to the
40    Humans infected with the dimorphic fungus Blastomyces dermatitidis develop strong T-lymphocyte res
41                           African strains of Blastomyces dermatitidis differ from North American stra
42          Isolates were selected based on low Blastomyces dermatitidis DNA probe values and/or atypica
43       We report that the pathogenic yeast of Blastomyces dermatitidis elaborates dipeptidyl-peptidase
44                               Infection with Blastomyces dermatitidis elicits strong antibody respons
45                          Pathogenic yeast of Blastomyces dermatitidis express a surface protein adhes
46 ccus neoformans, Histoplasma capsulatum, and Blastomyces dermatitidis from blood cultures.
47 (Portland, ME) for quantitative detection of Blastomyces dermatitidis galactomannan (GM) in urine usi
48  genetically engineered attenuated strain of Blastomyces dermatitidis given s.c. as a vaccine, wherea
49  tools available for genetic manipulation of Blastomyces dermatitidis have enhanced our ability to st
50 vaccines to induce protection against lethal Blastomyces dermatitidis infection in mice and is far mo
51 -dependent mechanisms of vaccine immunity to Blastomyces dermatitidis infection.
52 ed immunity is pivotal in host resistance to Blastomyces dermatitidis infection.
53                                              Blastomyces dermatitidis is a primary fungal pathogen of
54                                              Blastomyces dermatitidis is a thermally induced dimorphi
55 ulmonary infection with the dimorphic fungus Blastomyces dermatitidis often progresses and requires t
56                          The fungal pathogen Blastomyces dermatitidis produces an adhesin (WI-1) in y
57 R senses mannan on the surface of attenuated Blastomyces dermatitidis vaccine yeast and that MR(-/-)
58 found that serum inhibitory activity against Blastomyces dermatitidis was principally mediated by alb
59             Our previous studies showed that Blastomyces dermatitidis yeast activates the human compl
60 emory after vaccination with transgenic (Tg) Blastomyces dermatitidis yeasts that display a model Ag,
61 oides posadasii, Histoplasma capsulatum, and Blastomyces dermatitidis), have soared recently, spurrin
62                                              Blastomyces dermatitidis, a dimorphic fungus and the cau
63 f serum factors or MBL on the interaction of Blastomyces dermatitidis, a pulmonary fungal pathogen, w
64 gi Histoplasma capsulatum, Coccidioides spp, Blastomyces dermatitidis, and Paracoccidioides brasilien
65 role in phagocyte recognition and killing of Blastomyces dermatitidis, but little is known about how
66 igatus, Aspergillus terreus, Bipolaris spp., Blastomyces dermatitidis, Cladophialophora bantiana, Fus
67  to amplify DNA from Histoplasma capsulatum, Blastomyces dermatitidis, Coccidioides immitis, Paracocc
68 , a virulence factor in the dimorphic fungus Blastomyces dermatitidis, for expression in yeast and my
69 Blastomyces adhesin 1), a 120-kDa protein of Blastomyces dermatitidis, functions as an adhesin, immun
70  Pseudallescheria boydii, Rhizopus arrhizus, Blastomyces dermatitidis, Histoplasma capsulatum, and Sp
71     BAD1, an adhesin and immune modulator of Blastomyces dermatitidis, is an essential virulence fact
72                  BAD1, a virulence factor of Blastomyces dermatitidis, is displayed on yeast and rele
73 ved in specimens from patients infected with Blastomyces dermatitidis, Paracoccidioides brasiliensis,
74                               Yeast forms of Blastomyces dermatitidis, Sporothrix schenckii, and Hist
75                                           In Blastomyces dermatitidis, the agent of blastomycosis, a
76 nsia crescens, an agent of adiaspiromycosis, Blastomyces dermatitidis, the agent of blastomycosis, an
77                                              Blastomyces dermatitidis, the etiologic agent of blastom
78 on caused by the soil-based dimorphic fungus Blastomyces dermatitidis, which is endemic throughout mu
79 L in vaccine immunity to the fungal pathogen Blastomyces dermatitidis.
80 al report of hard-palate infection caused by Blastomyces dermatitidis.
81 ry delivery of an attenuated vaccine against Blastomyces dermatitidis.
82 e fluid (BALF) on the interaction of BAM and Blastomyces dermatitidis.
83 infection with Strongyloides stercoralis and Blastomyces dermatitidis.
84 from Candida glabrata, Candida albicans, and Blastomyces dermatitidis.
85  Certain elements resembled budding cells of Blastomyces dermatitidis.
86 t are shared with Histoplasma capsulatum and Blastomyces dermatitidis.
87 ection, and it notably gave a false-positive Blastomyces DNA probe laboratory result.
88 asexualis isolates also resulted in positive Blastomyces DNA probe results, while Spiromastigoides sp
89 stoplasmosis (also positive by the MiraVista Blastomyces EIA).
90 %), from 8 countries throughout all regions; Blastomyces emzantsi (n = 9, 26%), from South Africa; B.
91 , and the other (n = 8) is described here as Blastomyces emzantsi sp. nov.
92    All sequenced isolates were identified as Blastomyces gilchristii and clustered into a distinct ou
93 omycosis due to Blastomyces dermatitidis and Blastomyces gilchristii is a significant cause of respir
94 elated to but distinct from B. dermatitidis, Blastomyces gilchristii, and Blastomyces parvus The firs
95 a and caused by Blastomyces dermatitidis and Blastomyces gilchristii.
96                                              Blastomyces helicus (formerly Emmonsia helica) is a dimo
97                                              Blastomyces helicus causes fatal pulmonary and systemic
98                                              Blastomyces is a dimorphic fungus that infects persons w
99      Comparison to the MiraVista Diagnostics Blastomyces (MVB) EIA showed 100% positive (24 of 24), n
100                    Our findings suggest that Blastomyces O-mannan displayed by Eng2 induces a form of
101  antigen yielded no detectable reaction with Blastomyces of Histoplasma antiserum by ID.
102 . dermatitidis, Blastomyces gilchristii, and Blastomyces parvus The first group (n = 12) corresponded
103 yped case isolates that comprised 4 species: Blastomyces percursus (n = 22, 65%), from 8 countries th
104 rresponded to the recently described species Blastomyces percursus, and the other (n = 8) is describe
105                      Repeat testing with the Blastomyces probe demonstrated false-positive results wi
106  an enzyme immunoassay (EIA) compared to the Blastomyces quantitative EIA from MiraVista Diagnostics
107                                  Using naive Blastomyces-specific transgenic CD4(+) T cells, we found
108 s spp. (n = 9), Histoplasma spp. (n = 7) and Blastomyces spp. (n = 3).
109                                              Blastomyces spp. antigen testing was evaluated over a 10
110                              Transmission of Blastomyces via donor allograft in solid organ transplan
111                              In lung cancer, Blastomyces was associated with tumor tissues.
112                                        BYS1 (Blastomyces yeast-phase-specific 1), first identified by

 
Page Top